CytoDyn Announces President Takes Medical Leave of Absence
Antonio Migliarese assumes interim President role
Dr. Melissa Palmer appointed interim Chief Medical Officer
Dr. Salah Kivlighn joins CytoDyn as clinical and strategic advisor
Related news for (CYDY)
- CytoDyn Releases ESMO Breast Cancer Meeting Poster
- CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
- CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
- CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany
- CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab